参考文献:
[1] Yuen CA, Chu E, O'Connell R, et al. Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma. Pharmaceuticals (Basel). 2025 Jul 13;18(7):1039.
[2]中华医学会整形外科分会神经纤维瘤病学组. 丛状神经纤维瘤的全病程管理专家共识(2025版)[J]. 中华医学杂志,2025,105(05):331-345.
[3]Jun Liu, et al. Long-term efficacy and predictors analysis of selumetinib in Chinese adult patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. 2025 Global NF Conference poster.
[4]Gandhi, T., & Mella, D. (2025). INNV-22. A case report of the first adult neurofibromatosis type 1 patient treated with mirdametinib. Neuro-Oncology, 27(Supplement_5), v229-v229.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
文章原文

